Chief executive expects copycat medicines to be a key market with higher margins than traditional generics as governments seek to cut healthcare costs Source
This site uses Cookies to dispense or record information with regards to your visit. By continuing to use this site you agree to the terms outlined in ourCookies used here:Privacy / Disclaimer,